Introduction
Important morphological changes occur in platelets during their activation at sites of vascular injury. The cells loose their resting discoid shape to become spheroid and contracted, emitting membrane blebs and longer extensions [1] [2] [3] [4] . Once in contact with a surface, the spheroid platelets extend long filopodia and finally spread over it by emitting thin, sheet-like lamellipodia 1, 2 . Myosin activation plays a central role in the cytoskeletal rearrangements underlying these changes in morphology. Myosin becomes activated after phosphorylation of the myosin regulatory light chain (RLC), which results from both calcium-regulated myosin light chain kinase activity and Rho kinase-regulated myosin phosphatase activity [5] [6] [7] [8] .
Activated myosin assembles into short filaments through the myosin heavy chain and interacts mainly with central actin filaments. Myosin has been proposed to participate in several platelet contractile functions such as platelet spheration, contraction and stress fiber formation, and fibrin clot retraction. Platelet spheration and contraction as observed in the aggregometer closely correlate with phosphorylation of the RLC 9, 10 and are prevented when RLC phosphorylation is inhibited 6, 7, 9, 10 . Myosin has also been shown to be associated with stress fiber-like structures in spreading adherent platelets 11 . In addition, myosin could play a role in platelet secretion as it is decreased by inhibition of myosin RLC phosphorylation 5, [12] [13] [14] [15] .
Finally, a role of myosin in clot retraction has long been suspected in view of the necessity for a contractile force and was recently confirmed using a direct inhibitor of myosin activity 16 .
Several of these platelet functions are altered in patients carrying mutations in the MYH9 gene encoding the non-muscle myosin heavy chain IIA (NMHC-IIA) which is the only myosin heavy chain isoform present in platelets 17 . Mutations in this gene are responsible for the so-called MYH9-related disorders, which encompass several autosomal dominant diseases previously classified as May-Hegglin anomaly, Fechtner syndrome, Sebastian syndrome or Epstein syndrome [18] [19] [20] . Different mutations have been reported that in all cases result in -3 -only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013 . bloodjournal.hematologylibrary.org From abnormal NMHC-IIA. All these patients share the triad of thrombocytopenia, large platelets and characteristic leukocyte inclusions (Döhle-like bodies) composed of ribosomes, endoplasmic reticulum and abnormal myosin aggregates 21, 22 . Platelets from these patients fail to undergo shape change in the aggregometer in response to agonists but display normal aggregation 18, [23] [24] [25] . While most patients are asymptomatic or have a mild bleeding tendency, a few suffer from significant bleeding, either spontaneously or during childbirth or surgical procedures 26 . Other manifestations may occur such as cataracts, sensorineural deafness or nephritis, which is consistent with the wide tissue expression of NMHC-IIA. Most of these other manifestations appear later during adulthood, probably because of the presence of other heavy chain isoforms in the tissues involved that compensate for the abnormal NMHC-IIA 20, 27, 28 . The molecular mechanisms leading to the platelet abnormalities are still subject to debate. Some studies suggested that mutations in MYH9 led to a dominant negative effect, "poisoning" the wild-type myosin 21, 29 , others showed that the disease resulted from a haploinsufficiency 30 and a more recent study suggested haploinsufficiency in the megakaryocytic lineage associated with a dominant negative effect in granulocytes 31 .
To explore the role of myosin and the effects of myosin deficiency on the hemostatic functions of platelets, we generated mice with disruption of MYH9. Since previous studies have shown early embryonic mortality in MYH9-/-mice 28, 32 (and unpublished data), we used the loxP-Cre system to restrict the MYH9 knock out to the megakaryocyte lineage. Mice carrying a floxed MYH9 first exon were crossed with transgenic mice carrying crerecombinase under the regulation of the platelet PF4 promoter 33 . Inactivation of MYH9 in megakaryocytes resulted in a severe defect in platelet myosin expression with a phenotype resembling that of MYH9-related diseases, including thrombocytopenia, large and immature platelets and impaired platelet contractile activity. Our data show that whereas platelet aggregation and secretion responses were only moderately affected, myosin deficiency led to
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Materials and Methods
Materials. Equine tendon collagen was from Nycomed (Germany) and human fibrinogen from Kabi (Sweden). BSA, Busulfan, thrombin and anti-NMHC-IIA antibody were from Sigma-Aldrich (France). Blebbistatin was from Calbiochem (VWR, France). Eptifibatid was from GlaxoSmithKline. Jon/A-PE antibody, FITC-labeled anti-fibrinogen antibody, anti-CD41/CD61-PE and anti-CD61 (β3 integrin) antibodies were from Emfret (Germany). Anti- were crossed with transgenic mice selectively expressing cre-recombinase in the megakaryocyte lineage, under control of the BAC PF4 (platelet factor 4) promoter (100% C57BL/6) 33 . Mice expressing cre gene and heterozygous for the MYH9 recombination were intercrossed to obtain littermate mice homozygous for the wild-type (WT) MYH9 allele (+/+ mice) and homozygous for the recombined allele (MYH9Δ or -/-mice), or heterozygotes (+/-mice).
-5 - (20-25g) were anesthetized by inhalation of isoflurane.
The extremity of the mouse tail was cut transversally with a scalpel (3 mm) and immediately immersed in 0.9% isotonic saline at 37°C. The bleeding time was defined as the time required for arrest of bleeding and when necessary bleeding was stopped manually at the 10 min time point to prevent death.
Clot retraction. Citrated PRP (adjusted to 3.10 5 platelets/µL, 300 µL) obtained by centrifugation of whole blood at 250g for 10 minutes was stimulated with thrombin (10 U/mL) in the presence of CaCl 2 (20 mM) and incubated at 37°C for up to 5 hours, together with 2 µL of erythrocytes to enhance the contrast of the clot.
Platelet survival. Platelet survival time was determined using a modified method adapted from Peng et al. 34 by in vivo biotinylation of platelets through intravenous injection of sulfo-NHS-Biotin (twice 2 mg/kg with 30 minutes interval, 5 mice of each genotype). Biotinylated platelets were counted daily for 4 days at 7 hour intervals. The percentage of biotinylated platelets was determined using flow cytometry by double labeling of whole blood with streptavidin-PE (100 µg/mL) and anti-CD41/CD61-PE.
Platelet activation studies. Blood was drawn from the abdominal aorta, platelets were washed and aggregation performed as described 35 . Western blotting. Frozen ground tissues lysates were prepared in 1% Triton X100 buffer. were immediately extracted and quantified as described 38 .
Electron microscopy. Platelets were fixed directly in the aggregometer cuvette with 2.5% glutaraldehyde in 0.1M cacodylate buffer, pH 7.2, containing 2% sucrose. Cells for transmission electron microscopy (TEM) were processed as described previously 35 and ultrathin sections were examined under a Philips CM120 Biotwin electron microscope (FEI, Eindhoven, The Netherlands) at 120 kV. Scanning electron microscopy (SEM) was performed as described elsewhere 37 under a Sirion scanning electron microscope (FEI) at 5 kV.
In vitro model of thrombosis on immobilized collagen under flow conditions. Platelet thrombus formation was studied as described previously 39 . Control wt mice were injected intraperitoneously with busulfan (30 mg/kg) 14 days before drawing blood so as to obtain a thrombocytopenia ranging from 1.10 5 to 3.10 5 platelets/µL. MYH9Δ mice were injected with vehicle (polyethylene-glycol). Hirudin anticoagulated whole blood was perfused through collagen-coated glass capillaries at a shear rate of 3,000 s -1 . For SEM analysis, the capillaries were rinsed with saline after blood perfusion for 2 minutes and the surface was fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2). The capillaries were sectioned longitudinally, treated and examined as described previously 40 .
-8 - Statistics. The results are expressed as mean±sem. The significance of the differences between genotypes was evaluated using Student t-test or Student Paired t-test, as mentioned.
Results

Generation of megakaryocyte-specific MYH9Δ mice
In order to generate a viable animal model with NMHC-IIA deficiency in the megakaryocytic lineage, we ablated exon 1 from the MYH9 gene using a PF4-promoter driven
Cre-loxP system. Exon 1 was excised in vivo (MYH9Δ) by crossing MYH9 Flx/Flx mice with transgenic animals expressing cre-recombinase specifically in megakaryocytes under the control of the PF4 promoter 33 . MYH9
Flx/wt
; PF4-cre mice were intercrossed to produce
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MYH9Δ mice exhibit severe NMHC-IIA deficiency
To determine the extent and tissue specificity of the NMHC-IIA deficiency, lysates from platelets and several tissues were analyzed by Western blotting. Normal myosin content was detected in kidney, lung, liver and spleen of MYH9Δ mice (Figure 1b 42, 43 . Platelet expression of the residual NMHC-IIA was visualized by immunofluorescence microscopy. As seen in Figure 1d , the intensity of NMHC-IIA labeling was considerably reduced in all MYH9Δ platelets compared to control.
MYH9Δ mice display thrombocytopenia and altered platelet morphology
Mice deficient in NMHC-IIA reproduced some of the characteristic features of MYH9-related diseases in humans. These mice exhibited thrombocytopenia with an average platelet count representing around 40% of wild-type (wt: 1028±63x10 3 platelets/µL, heterozygous: (Figure 2b and 2c ). Ultrastructural analysis of MYH9Δ
washed platelets revealed some heterogeneity with a mixed population of normal discoid and more ovoid morphology, compared to the control platelets (Figure 2b and 2c) . A large proportion of these platelets contained large amounts of rough endoplasmic reticulum (RER), typical of young or immature cells as observed both by electron microscopy (15.3% of MYH9Δ platelets vs. 0.5% of wt platelets, respectively) ( Fig. 2d) and thiazole orange labeling (data not shown). Ultrastructure of platelets from heterozygous animals appeared normal (data not shown). There was no defect in expression of some major platelet glycoproteins (α IIb β 3 , GPIbα, GPIbβ, GPV) as detected by flow cytometry (data not shown).
In vivo platelet half-life was similar in the two genotypes (survival time: 112.4±6.1 vs 101.6±4.6 hours for wt and MYH9Δ mice, respectively, n=5, p>0.05), suggesting that the thrombocytopenia does not result from an accelerated clearance from the circulation and that the increased proportion of reticulated cells mostly reflects a defect in the formation of mature platelets.
MYH9Δ mice exhibit a strong increase in bleeding time and a total absence of clot retraction MYH9Δ mice presented no evidence of spontaneous bleeding or hemorrhage. Tail bleeding times were performed to explore primary hemostasis functions following injury.
Control wt mice had an average bleeding time of 78±16 s (Fig. 3a ). An increased bleeding
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From time up to 400 s was observed in some heterozygous mice but the average bleeding time was not significantly different from the wt (135±39 s). By contrast, all the MYH9Δ mice bled for more than 600 s. It is noteworthy that the bleeding was so important in these mice that they died by 20 minutes unless the wound was manually cauterized (data not shown). By comparison, busulfan-induced thrombocytopenia in wt mice (ranging from 0.3 to 0.6x10 6 platelets/µL which is comparable to MYH9Δ mice) did not significantly affect the bleeding time (173± 24 s) (Figure 3a) . For (Table 1) . Altogether, there appears to be a minor impact if any of myosin-deficiency on platelet aggregation and secretion in suspension. In order to assess whether the residual myosin expression could play a part in the near normal aggregation and secretion observed, platelets were pretreated with blebbistatin (100 µM), an inhibitor of non-muscle myosin II activity 44, 45 . Under these conditions, blebbistatin totally prevented initial platelet shape change in control platelets. However, no further inhibition of platelet aggregation or secretion was observed in MYH9Δ platelets (data not shown). Thus, these data show that myosin does not play a crucial role in these functions.
Myosin-deficient platelets display impaired contractile shape change and stress fibers formation
Platelet shape change was further investigated in the aggregometer following addition of 5 µM ADP in the absence of fibrinogen and in the presence of the integrin α IIb β 3 antagonist Eptifibatid to prevent platelet aggregation. As shown in Figure 4b , the shape change was almost abolished in MYH9Δ as compared to control platelets while platelets from heterozygous mice exhibited normal shape change (data not shown). Observation by SEM revealed the presence of 92% discoid platelets with only a few or no membrane extensions whereas in the control 72% of the platelets underwent rounding and contraction (Figure 4b ).
Platelets from heterozygous animals behaved similarly to the control platelets (data not shown). Treatment of platelets with blebbistatin abolished rounding and contraction of control platelets by 96% and had no further significant effect on MYH9Δ platelets (data not shown).
Platelet spreading and stress fibers formation were then studied during adhesion of platelets to a fibrinogen-coated surface. When pre-stimulated with thrombin, both wt and MYH9Δ platelets were able to adhere to the surface and extend lamellipodia, as was revealed by phalloidin labeling of actin fibers (Figure 5a ) and SEM after triton X100 permeabilization (Figure 5b ). However, MYH9Δ platelets were unable to form stress fiber-like structures contrary to control platelets. Instead, long actin filaments were observed throughout the cytoplasm together with short filaments at the leading edge, and the final mean surface area was increased by 10% (n=736 and 670 platelets for control and MYH9Δ platelets, respectively, p<0.0002 using Student t-test).
Outside-in signaling is strongly impaired in myosin-deficient platelets
The absence of stress fibers formation on a fibrinogen matrix together with absent clot retraction prompted us to evaluate signaling through integrin αIIbβ3. Integrin activation was evaluated in control and MYH9Δ mice following activation by collagen (100 µg/mL) or thrombin (1 U/mL) in the absence of stirring. The level of activated integrin was measured by flow cytometry using an antibody directed against the activated form of the integrin (Jon/A PE antibody 37 ) or against integrin-bound fibrinogen. In both cases, thrombin stimulation led to a significant decrease in αIIbβ3 activation that was not observed with collagen (Figure 6a ). Outside-in signaling was then evaluated by the phosphorylation of the integrin β3 during the course of thrombin-induced platelet aggregation. As shown by immunoblotting, thrombin stimulation led to the phosphorylation of integrin β3 as early as 60 seconds following agonist addition in control platelets. By contrast, in MYH9Δ platelets, there was impairment in the phosphorylation of the integrin. By 3 minutes, the amount of integrin β3 phosphorylated in myosin-deficient platelets was decreased by 65% as compared to the wt platelets, indicating that myosin plays a role in integrin outside-in signaling (Figure 6b ).
To further evaluate defective outside-in signaling, we measured the activity of PI 3-kinase. Particularly, the synthesis of a major part of one of its product, PtdIns(3,4)P 2 , is indeed dependent upon the engagement of the integrin 46, 47 . The levels of PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 were measured following platelet stimulation by thrombin or collagen. While -14 -only.
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Thrombus organization is impaired in vitro under flow conditions and in vivo
To evaluate the role of myosin in the process of thrombus formation, we first investigated thrombus growth in vitro in a whole blood perfusion assay over a fibrillar collagen matrix under arterial shear rate conditions (3,000 s -1 ) 48 . Keeping in mind the decreased platelet count in MYH9Δ mice, wt mice were treated with busulfan to reach thrombocytopenia levels comparable to that of MYH9Δ mice (290±115x10 3 platelets/µL for busulfan-treated mice, and 220±103x10 3 platelets/µL for MYH9Δ mice). After 2 min perfusion, analysis of the flow chamber by SEM revealed that the structure of the thrombi was totally different between both genotypes. In the control condition, the compact aggregates formed were composed of contracted platelets tightly packed together. In contrast, aggregates of MYH9Δ blood contained only a few layers of platelets that did not have contracted bodies and were rather flat with spread morphology, and were loosely packed as compared to the control cells (Figure 7a ).
The capacity of MYH9Δ mice to develop a thrombus was then evaluated in vivo in a carotid artery thrombosis model where injury was induced by topical application of FeCl 3 and visualized by intravital microscopy 41 ( Figure 7b and supplemental videos). Busulfan-treated wt mice were used as control. These mice exhibited a platelet count of 312±57x10 3 platelets/µL (n=8) similar to platelet counts in MYH9Δ mice used in this experiment (317±76 x10 3 platelets/µL). In control mice, the thrombus was compact and occupied the whole injured surface as judged by the uniform intensity of fluorescence. By contrast, in MYH9Δ mice, the injured surface was not uniformly covered as observed by the lack of homogeneity of the -15 -only.
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Discussion
In the present study, we addressed the question of the role of myosin and contractile activity in platelet functions. We established a mouse strain with megakaryocyte-restricted disruption of the MYH9 gene, leading to severe NMHC-IIA deficiency in platelets amounting to less than 3% of the wt platelets. The reason for the presence of residual very low amounts myosin could be due to an incomplete excision of the MYH9 exon 1 by the cre-recombinase in the megakaryocytes. Another possible explanation could be that the residual myosin reflects the long half-life of the NMHC-IIA synthesized before the time where the PF4 promoter becomes functional and promotes the expression of the Cre-recombinase. The appearance in the MYH9Δ platelets of a protein with a slightly lower molecular weight indicates that some synthesis from exon 1-deleted mRNA occurs. The presence of this protein in low amounts suggests that either the transcription or the traduction is not efficient, or that the truncated protein is unstable. In addition, the defect in NMHC-IIA expression led to a decrease in myosin RLC expression. This probably results from instability of the RLC in the absence of the heavy chain as already observed in Dictyostelium discoideum 43 and more recently in Drosophila melanogaster 42 .
MYH9Δ mice presented a platelet phenotype closely resembling that of MYH9-related disorders in humans and consisting essentially of thrombocytopenia and large platelets, with an absence of agonist-induced platelet shape change 18 . However, due to its restriction to the megakaryocytic lineage, these mice lack additional defects observed in other tissues in
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The major observations were that MYH9Δ mice exhibited a considerable increase in the bleeding time and total absence of clot retraction. It is unlikely that the thrombocytopenia is the sole reason why MYH9Δ mice bled to death upon tail section. Indeed, busulfan-treated wt mice having thrombocytopenia in the same range as MYH9Δ mice displayed no such prolongation of the bleeding time. Moreover, in other severely thrombocytopenic mice such as cMpl, β1 tubulin or GPIbβ knockout mice 40, 49, 50 the bleeding tendency was likewise less pronounced. Hence our data suggest that altered platelet functions due to myosin deficiency are responsible for the defects.
The total absence of clot retraction may contribute to increase the bleeding time since impaired clot retraction has been shown to lead to rebleeding in several mouse models 51, 52 . It is noteworthy that defective clot retraction has only been reported in a few MYH9 patients 53 and one study mentioned normal clot retraction in a May-Hegglin subject who suffered from bleeding tendency 54 . One may speculate that some myosin activity are preserved in these patients, despite the presence of mutant forms of myosin IIA which are able to interact with the non mutated counterpart, thus "poisoning" the normal protein.
What makes the observation of increased bleeding time even more puzzling was that in vitro platelet aggregation and secretion were almost not altered in MYH9Δ mice. The very modest impact of myosin deficiency on secretion was unexpected since early observations that the cytoskeleton directs granule centralization in platelets had long led to the speculation that actomyosin should provide a contractile force facilitating the release of granule contents [55] [56] [57] . Furthermore, inhibitors of myosin light chain kinase or Rho-kinase have been shown to block phosphorylation of the myosin light chain, a prerequisite for myosin activation, and to -17 -only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From inhibit the release reaction, suggesting that actomyosin contraction is required for granule secretion 5, [12] [13] [14] [15] . Our results indicate that myosin contraction, while facilitating the release reaction following weak platelet stimulation, is in fact dispensable for platelet secretion when increasing agonist concentrations.
More unexpected, in view of the modest impact on platelet aggregation and secretion, was the alteration in thrombus formation both in vitro under high shear flow and in vivo. The disorganization of the thrombus in myosin-deficient mice is accompanied by an increase in emboli detaching from the thrombi. This effect on thrombus stability is most probably due to a decrease in aggregate stability under high shear forces that could result from both the absence of aggregate compaction and the defect in outside-in signaling. Indeed, aggregate compaction would be expected to allow the thrombus to resist shear forces and also to reduce the space between platelets, thus increasing local concentrations of released agonists. The capacity of platelets to remain in close contact to each other despite the shear forces rely on the engagement of integrins with their ligands, leading to signal transduction that reinforces the interactions between platelets. The αIIbβ3 integrin outside-in signaling resulting from fibrinogen binding leads to tyrosine phosphorylation of several proteins including the β3 subunit itself, activation of the phosphoinositide metabolism, further cytoskeleton reorganization, enhancement of platelet activation and improved stability of the aggregates 47, 58 . Our results show that myosin plays a role in platelet integrin outside-in signaling as observed by a decrease in both PtdIns(3,4)P 2 accumulation and the β3 subunit phosphorylation. Phosphorylation of β3 allows direct interaction of the integrin with myosin.
Platelets from DiYF mice, in which β3 cannot be tyrosine phosphorylated, exhibit like patients have a less severe hemorrhagic syndrome than mice, the mechanisms described here nevertheless may explain part of the defects of hemostasis observed in the patients.
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